← Browse by Condition
Medical Condition
advanced urothelial carcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1
NCT07241793 Phase 2
Recruiting
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Enrollment
96 pts
Location
China
Sponsor
Sun Yat-sen University
NCT05929235 Phase 1
Recruiting
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Enrollment
120 pts
Location
United States
Sponsor
Flare Therapeutics Inc.